Department of Medicine
Daniel Olson’s research centers around improving the efficacy and safety of immunotherapy. This includes investigator-sponsored trials (IST) targeting mechanisms of resistance to programmed cell death protein 1 (PD-1) antibody therapy. He recently published the promising results of a phase II IST trial of pembrolizumab plus ipilimumab in PD-1 antibody-refractory patients with melanoma. He has authored two additional phase I trials in PD-1 antibody-refractory patients, one at the American Society of Clinical Oncology/American Association for Cancer Research Methods in Clinical Cancer Research Workshop. He also has a translational interest in mechanisms of immune-related adverse events.
Olson will continue his work in the melanoma program and will also join the clinical and experimental therapeutics program at the University of Chicago Medicine, where he will help to open, design, and run a broad portfolio of immunotherapy-focused trials and will have a focus on solid tumor cell therapy protocols, with a goal to expand and support these trials within the University of Chicago Comprehensive Cancer Center.
His work has been published in The Journal of Clinical Oncology, Clinical Cancer Research, The Journal of Immunotherapy of Cancer, and Melanoma Research.
Olson received his MD from Rush Medical College. He completed his internal medicine residency at Northwestern University and fellowships in oncology and in clinical pharmacology and pharmacogenomics at the University of Chicago, during which time he received several merit awards from the American Society of Clinical Oncology.